An investigation on the behavioral and hypothermic effects of yohimbine: interaction with drugs affecting central and peripheral monoamines.
D006916:5-Hydroxytryptophan / Q000494:pharmacology; D000374:Aggression / Q000187:drug effects; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D001545:Benserazide; D001679:Biogenic Amines / Q000378:metabolism*; D001831:Body Temperature / Q000187:drug effects*; D002395:Catecholamines / Q000494:pharmacology; D002714:Chlorisondamine / Q000494:pharmacology; D003000:Clonidine / Q000494:pharmacology; D003864:Depression, Chemical; D004295:Dihydroxyphenylalanine / Q000494:pharmacology; D010134:Fenclonine / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D008297:Male; D008784:Methysergide / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects; D010293:Pargyline / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D011941:Receptors, Adrenergic / Q000187:drug effects; D013239:Stereotyped Behavior / Q000187:drug effects; D015016:Yohimbine / Q000494:pharmacology*
D001679:Biogenic Amines; D002395:Catecholamines; D011941:Receptors, Adrenergic; D010643:Phenoxybenzamine; D015016:Yohimbine; D004295:Dihydroxyphenylalanine; D001545:Benserazide; D001285:Atropine; D008238:Lysergic Acid Diethylamide; D010293:Pargyline; D011433:Propranolol; D006916:5-Hydroxytryptophan; D000661:Amphetamine; D006220:Haloperidol; D002714:Chlorisondamine; D003000:Clonidine; D001058:Apomorphine; D010134:Fenclonine; D008784:Methysergide; D010646:Phentolamine